Member Info for hants

Plenty of us still here I'm sure mfm.

There's just not much to talk about at the moment beyond speculation. "Is it us?"

Something which I find baffling is how quickly the Government can decide it's safe to start injecting it's population with a new type of vaccine with no long term data on side effects... but how long it takes to simply validate a test.

It's either funny or terrifying.

I'm not too bothered about an RNS personally. What I'm excited for is another gripping article from the Yorkshire Post. Yellow Jersey PR did a great job getting them on board with the Avacta story.

Well said. Company communication is poor at best. Let's hope they pull something good out the bag soon.

Despite the very long wait and bumps in the road, I remain very positive and mostly for one single reason...

Avacta simply CANNOT afford to balls this up.

Failure to deliver will destry Sir Als credibility. Current issues such as the change to swab and his house buying can be forgiven, but a total failure cannot.

Secondly, delivery of a test which is anything less than excellent will destroy the belief in Affimers - the core of the company.

Failure is simply not an option here.

Fantastic post. Just giving it another bump back to the top.

TWatcher, the type of nasal swab is very important. Nasopharyngeal is very unpleasant and not ideal for a product being used by the consumer. Anterior nasal is just the accessible part of your nose and therefore not painful or unpleasant. Anterior will have the much larger uptake imo, won't be easy to get the public doing it otherwise.

Somebody please correct me if I'm wrong but I understand as follows:

Innova is anterior swab
Roche is nasopharyngeal
Avacta is working on both anterior swab and on saliva
ISH is nasopharyngeal

Hopefully JonesRichard comes back too

There's been a lot of posts over the last few months saying just get a test out there and refine it later. I think we can all see now why thats not a good idea. I don't like the slowness either, but it's certainly preferable to the sh*t show which would follow if it's weren't done right...

Nothing to do with Avacta whatsoever. Move along.

200 excl. China I believe, pl75?

Fardistanthills, I agree with you and posted similar. Any good news would be significantly tainted by it being a swab without the market having sufficient time to absorb that information beforehand.

If BBI have redesigned the test and made it a more standard device using their own components, with Affimer reagents from Avacta, perhaps we will see this come to market much faster than we expect? Should we still even be waiting for a tech transfer RNS? Perhaps this is there already.

("A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples")

Thanks for the update Global.

Selling low still working out well for you?

Forgot to add my main point to my post which is.. it would absolutely not surprise me if the TT RNS followed a only a handful of days behind.

Afamaman, good observation there. Tech transfer must be extremely close and I think we'll see a lot of sellers becoming buyers again very soon.

Just a thought and possibly talking complete rubbish here, but it's possible that today's RNS and video were with a primary purpose to reset expectations onto swab and away from saliva. Can you imagine if the TT RNS had arrived and it was for a swab test that we didn't know about. What a mess that would've been! At least this way the sellers who aren't happy will clear, leaving holders whos expectations are set correctly.

Lots of low post count idiots coming out of the woodwork today.

Defnitely £2 by close Sagetrade! In all seriousness though, once the sentiment pendulum swings back the other way (like it did last week), we will, IMO, almost certainly have another bull run to test the 105 EMA again. This is still somewhat depressing as even if it holds it will leave us 30 to 40p away from where we were pre vaccine drop, but it's better than a quid!

Todays price drop is nothing to do with "MM's playing games" as people like to say. It makes it almost a complete certainty that neither of the "big one" RNS are going to land... I'm referring to BAMS and more importantly the LFT. This means you can fairly safely sell your shares and sit on the sidelines for at least a few days without needing to worry too much about missing out. You'll probably buy back cheaper. Worst case you may lose a few% dependings on the shares daily movements, but you're unlikely to get a big rise.

Furthermore, because those hoping for a nice trade on a big rise will also sell out.

The thing is though, they'll probably all be back, plus more, soon. Assuming no negative left field news lands (like eating brussel sprouts cures the rona or something like that), this RNS has provided the confirmation everybody wanted that everything is fine and nothing disastrous has happened.

Here's my highlights from the RNS:

1. We now have ANOTHER type of test in a nasal swab LFT, in addition to saliva. This derisks us significantly IMO as even a 50% failure rate becomes acceptable. We know from Innova that even though swabbing isn't ideal, the tests are still being mopped up.

2. "A highly scalable test device using readily available components and routine manufacturing processes has now been shown to have a sensitivity for coronavirus spike protein in laboratory samples better than 300 pg/ml which is in the range expected for spike protein in clinical samples."

I like the use of the word 'better'... so it works and exceeds the sensitivity requirement. We already know Affimers are specific so that's two boxes ticked.

3. Here's something I don't like at face value:

"In parallel BBI Solutions is working to finalise and validate the manufacturing process so that the Group can carry out a full clinical validation on the final product to support the regulatory approval process."

However, it also says "The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study" ... which would indicate to me that tech transfer must be imminent.

I cannot see that any type of preliminary clinical evaluation would have started if the test wasn't very close to the finished article. That wouldn't make sense. To my mind, this also says the test(s) will be as close to perfect as they can be. Sir Al has already told us he won't push risk down the line from TT. Clearly they already have a test which works and is extremely close to the final product as they're starting to evaluate it, so anything happening now must be finessing it.

Finally.... "Furthermore, we remain on track to submit the UK regulatory application, or CTA, for AVA6000 pro-doxorubicin before the end of the year to allow first-in-human trials of the pre|CISIONTM chemotherapy platform at several clinical trial sites in the UK early in 2021."

It's the 23rd November today...

Neutronic, we will definitely be notified by RNS when TT has been completed so good theory but it doesn't hold water I'm afraid.

I'm in ODX at a cheap price to catch the rise which will likely happen there soon enough. It's absolutely not a bad share imo. The problem is with the odx board is they think it's a serious multibagger which is just don't see happening. I would be surprised to see it break 150 ish. Beyond 2 and I would be shocked. Good returns from its current level with limited downside risk.